Literature DB >> 14764761

Prevalence and clinical associations of 10 defined autoantibodies in autoimmune polyendocrine syndrome type I.

Annika Söderbergh1, Anne Grethe Myhre, Olov Ekwall, Gennet Gebre-Medhin, Håkan Hedstrand, Eva Landgren, Aaro Miettinen, Petra Eskelin, Maria Halonen, Tiinamaija Tuomi, Jan Gustafsson, Eystein S Husebye, Jaakko Perheentupa, Mikhail Gylling, Michael P Manns, Fredrik Rorsman, Olle Kämpe, Thomas Nilsson.   

Abstract

The prevalence of autoantibodies against nine intracellular enzyme autoantigens, namely 21-hydroxylase, side-chain cleavage enzyme (SCC), 17 alpha-hydroxylase, glutamic acid decarboxylase 65, aromatic L-amino acid decarboxylase, tyrosine phosphatase-like protein IA-2, tryptophan hydroxylase (TPH), tyrosine hydroxylase, cytochrome P450 1A2, and against the extracellular calcium-sensing receptor, was assessed in 90 patients with autoimmune polyendocrine syndrome type I. A multivariate logistic regression analysis was performed for the presence of autoantibodies as independent predictors for different disease manifestations. Reactivities against 21-hydroxylase and SCC were associated with Addison's disease with odds ratios (ORs) of 7.8 and 6.8, respectively. Hypogonadism was exclusively associated with autoantibodies against SCC with an OR of 12.5. Autoantibodies against tyrosine phosphatase-like protein IA-2 were associated with insulin-dependent diabetes mellitus with an OR of 14.9, but with low sensitivity. Reactivities against TPH and, surprisingly, glutamic acid decarboxylase 65, were associated with intestinal dysfunction, with ORs of 3.9 and 6.7, respectively. TPH reactivity was the best predictor for autoimmune hepatitis, with an OR of 27.0. Hypoparathyroidism was not associated with reactivity against any of the autoantigens tested. No reactivity against the calcium-sensing receptor was found. Analysis of autoantibodies in autoimmune polyendocrine syndrome type I patients is a useful tool for establishing autoimmune manifestations of the disease as well as providing diagnosis in patients with suspected disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14764761     DOI: 10.1210/jc.2003-030279

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  55 in total

1.  Autoantigens in ovarian autoimmunity associated with unexplained infertility and premature ovarian failure.

Authors:  Seby L Edassery; Seerin V Shatavi; Jeremy P Kunkel; Charles Hauer; Cosima Brucker; Krishna Penumatsa; Yi Yu; James A Dias; Judith L Luborsky
Journal:  Fertil Steril       Date:  2010-06-01       Impact factor: 7.329

Review 2.  Lessons from primary immunodeficiencies: Autoimmune regulator and autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy.

Authors:  Gregory M Constantine; Michail S Lionakis
Journal:  Immunol Rev       Date:  2019-01       Impact factor: 12.988

3.  Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy.

Authors:  Choudhary Sonal; McLeod Michael; Torchia Daniele; Romanelli Paolo
Journal:  J Clin Aesthet Dermatol       Date:  2012-12

4.  Genetic disorders with immune dysregulation.

Authors:  Eleonora Gambineri; Troy R Torgerson
Journal:  Cell Mol Life Sci       Date:  2011-10-09       Impact factor: 9.261

5.  Pituitary autoantibodies in autoimmune polyendocrine syndrome type 1.

Authors:  Sophie Bensing; Sergueï O Fetissov; Jan Mulder; Jaakko Perheentupa; Jan Gustafsson; Eystein S Husebye; Mikael Oscarson; Olov Ekwall; Patricia A Crock; Tomas Hökfelt; Anna-Lena Hulting; Olle Kämpe
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-10       Impact factor: 11.205

Review 6.  Polyendocrine autoimmunity.

Authors:  Jennifer M Barker
Journal:  Curr Diab Rep       Date:  2005-04       Impact factor: 4.810

Review 7.  Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy.

Authors:  Kai Kisand; Pärt Peterson
Journal:  J Clin Immunol       Date:  2015-07-05       Impact factor: 8.317

8.  Autoimmune Regulator is required in female mice for optimal embryonic development and implantation†.

Authors:  Bryce D Warren; Soo H Ahn; Lynda K McGinnis; Geoffrey Grzesiak; Ren-Wei Su; Asgerally T Fazleabas; Lane K Christenson; Brian K Petroff; Margaret G Petroff
Journal:  Biol Reprod       Date:  2019-06-01       Impact factor: 4.285

9.  Long-lived plasma cells and memory B cells produce pathogenic anti-GAD65 autoantibodies in Stiff Person Syndrome.

Authors:  Marta Rizzi; Rolf Knoth; Christiane S Hampe; Peter Lorenz; Marie-Lise Gougeon; Brigitte Lemercier; Nils Venhoff; Francesca Ferrera; Ulrich Salzer; Hans-Jürgen Thiesen; Hans-Hartmut Peter; Ulrich A Walker; Hermann Eibel
Journal:  PLoS One       Date:  2010-05-26       Impact factor: 3.240

10.  A multidisciplinary approach to management of autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED).

Authors:  Mohammed Ramzy Gouda; Azzam Al-Amin; Heike Grabsch; Clare Donnellan
Journal:  BMJ Case Rep       Date:  2013-01-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.